Pre- and post-treatment transcriptional profiles of the heterogeneous ER+ tumor homogenate in response to AIs or fulvestrant in neoadjuvant studies of post-menopausal patients have enabled analysis of the sum of direct and indirect effects and compensatory responses after a relatively short (2–4 week) treatment course. This evidence concerns the gene ESR1 and neoplasm.